Bristol-Myers Squibb Co vs Quantumscape Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.5 (market cap $129.94B), while Quantumscape Corp trades at $6.38 (market cap $3.90B). The key difference: Bristol-Myers Squibb Co is far larger — about 33.3× Quantumscape Corp's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| BMY | QS | |
|---|---|---|
Market Cap | $129.94B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $18.44 |
52-Week Low | $42.60 | $4.89 |
Enterprise Value | $163.92B | $3.11B |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →